

Temporary benefit added to the *Palliative Coverage Drug Benefit Supplement (PCDBS)*

Due to the unavailability of Nozinan 25 mg/ml Injection (DIN 01927698) manufactured by Sanofi - Aventis, Loxapac 50 mg/ml Injection (DIN 02169991) manufactured by Sandoz Canada Inc., will be considered a temporary benefit for the *Palliative Coverage Drug Benefit Supplement (PCDBS)*.

As of **August 29, 2022**, all claims for Loxapac 50 mg/ml Injection (DIN 02169991) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at ab.bluecross.ca/providers/pharmacy-home.php.

If this situation continues to be a long-term matter, these products are subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* to remain as a benefit.

Removal of temporary benefits from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Acetylcysteine 20% Inhalation Solution (DIN 02243098) manufactured Sandoz Canada Inc., Acetylcysteine 20% Inhalation Solution USP (DIN 02459906) manufactured by Hikma Pharmaceuticals PLC was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Sandoz Canada Inc. has advised Alberta Blue Cross that the shortage of Acetylcysteine 20% Inhalation Solution (DIN 02243098) has been resolved.

As a result, Acetylcysteine 20% Inhalation Solution USP (DIN 02459906) will no longer be considered a temporary benefit for the *ADBL* after **September 30, 2022**. The above grouping was removed from the Critical Supply Product List on **August 31, 2022**.

Due to the shortages of Apo-Amitriptyline 75 mg Tablet (DIN 02403161) manufactured by Apotex Inc. and Elavil 75 mg Tablet (DIN 00754129) manufactured by AA Pharma Inc., Mar-Amitriptyline 75 mg Tablet (DIN 02429918) manufactured by Marcan Pharmaceuticals Inc was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Apotex Inc. and AA Pharma Inc. have advised Alberta Blue Cross that the shortages of Apo-Amitriptyline 75 mg Tablet (DIN 02403161) and Elavil 75 mg Tablet (DIN 00754129), respectively, have been resolved.

As a result, Mar-Amitriptyline 75 mg Tablet (DIN 02429918) will no longer be considered a temporary benefit for the *ADBL* after **October 3, 2022**. The above grouping was removed from the Critical Supply Product List on **September 1, 2022**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

